iPSC Cell Therapies Market Size and Analysis (2026-2035)

Revenue, 2025

USD 10.44 Billion

Forecast, 2035

USD 30.87 Billion

CAGR, 2026-2035

11.45%

Report Coverage

Global

iPSC Cell Therapies Market Trends for 2026

The global iPSC cell therapies market size was estimated at USD 10.44 billion in 2025 and is predicted to increase from USD 11.64 billion in 2026 to approximately USD 30.87 billion by 2035, expanding at a CAGR of 11.45% from 2026 to 2035.

The industry has transitioned from a purely research-driven field into a clinical reality, with the world’s first regulatory submissions for iPSC-based therapies now occurring in Japan and the U.S. Additionally, growing disease burden, AI integration, and new product launches are also promoting the market growth.

Key Takeaways

• The iPSC cell therapies market will likely exceed USD 11.64 billion by 2026.
• Valuation is projected to hit USD 30.87 billion by 2035.
• Estimated to grow at a CAGR of 11.45% starting from 2026 to 2035.
• North America dominated the global iPSC cell therapies market in 2025. 
• Asia Pacific is expected to be the fastest-growing region between 2026-2035.
• By therapy type, the allogeneic iPSC therapies segment held approximately 65% share in the market in 2025.
• By therapy type, the autologous iPSC therapies segment is expected to be the fastest growing during the forecast period. 
• By derived cell type, the cardiomyocytes segment held an approximate 29% share in the market in 2025.
• By derived cell type, the neurons/neural progenitors segment is expected to be the fastest-growing during the forecast period.
• By application type, the drug discovery & toxicology segment held approximately 39% share in the market in 2025.
• By application type, the regenerative medicine segment is expected to be the fastest growing during the forecast period.
• By end-user, the pharmaceutical & biotech companies segment held an approximate 48% share in the market in 2025.
• By end-user, the CROs & CDMOs segment is expected to be the fastest growing during the forecast period.

What are the iPSC Cell Therapies?

The iPSC cell therapies market is driven by growing chronic diseases, R&D funding, and technological advancements. The iPSC cell therapies refer to the therapies utilizing induced pluripotent stem cells (iPSCs) for the treatment or repair of damaged tissue or organs. They are used in gene therapy, tissue regeneration, disease modelling, personalized treatments, and drug testing.

What are the Applications of AI in the iPSC Cell Therapies Market?

AI provides a wide range of applications in the market, such as analysis of large datasets, enhancing cell quality, and reducing errors. It also detects the cell growth, its health, abnormalities, and differentiates them, with the use of automated imaging and monitoring. It also detects drug response, toxicity, optimizes various manufacturing parameters, and helps in the development of personalized therapies, using patient health data.

Trends & Future Outlook of the iPSC Cell Therapies Market

Expanding Therapeutic Applications

The growing advancements in iPSC cell therapies are driving the development of new treatment options for various metabolic, retinal, rare genetic disorders, and autoimmune disorders.

Shift Towards Personalized Therapies

The growing health awareness and focus on the development of patient-specific treatment are increasing the demand and development of various personalized autologous iPSC cell therapies with low rejection risks.

Focus On Curative Treatment Options

The companies are integrating advanced technologies such as CRISPR and other gene editing tools to develop novel curative therapies that can offer correction of genetic defects before transplantation.

Key Indicators and Highlights

Segmental Insights

By Therapy Type Insights

Why Did the Allogeneic iPSC Therapies Segment Dominate in the iPSC Cell Therapies Market in 2025?

The allogeneic iPSC therapies segment held the largest share of approximate 65% in the market in 2025, as they are favored for scalability and lower "off-the-shelf" costs. It also provided enhanced compliance with regulatory standards and improved batch consistency, which increased the quality of the products, which contributed to their increased use.

Autologous iPSC Therapies

The autologous iPSC therapies segment is expected to show the highest growth during the predicted time, as they are used for personalized neurology (e.g., Parkinson's) to avoid immune rejection. Moreover, the target-specific action, with low side effects and expanding applications are also increasing the adoption rates.

By Derived Cell Type Insights

How Cardiomyocytes Segment Dominated the iPSC Cell Therapies Market in 2025?

The cardiomyocytes segment led the market with approximate 29% share in 2025, due to the growth in cardiovascular disease. This increased the demand for regenerative treatment options, which increased their use. Moreover, their clear functional endpoints also increased their demand and adoption rates.

Neurons/Neural Progenitors

The neurons/neural progenitors segment is expected to show the fastest growth rate during the predicted time, due to their growing use in Parkinson’s and spinal cord injury trials. At the same time, growing neurodegenerative diseases and the low self-repair capacity of the neurons are also increasing their use in the development of new treatment options.

By Application Insights

Which Application Type Segment Held the Dominating Share of the iPSC Cell Therapies Market in 2025?

The drug discovery & toxicology segment held the dominating share of approximately 39% in the market in 2025, as the iPSC-derived cells were used to replace animal testing. They accelerated the R&D study and promoted their faster adoption. Furthermore, their affordability and scalability also encouraged their use.

Regenerative Medicine

The regenerative medicine segment is expected to show the highest growth during the upcoming years, as the iPSC cell therapies provide direct tissue replacement for AMD and heart failure. Moreover, the growing chronic diseases and expanding pipeline are also increasing their demand as a curative treatment option.

By End-User Insights

What Made Pharmaceutical & Biotech Companies the Dominant Segment in the iPSC Cell Therapies Market in 2025?

The pharmaceutical & biotech companies segment led the market with approximate 48% share in 2025, due to the growth in the R&D activities. Moreover, the growth in R&D investments and the expansion of the manufacturing infrastructure also increased their use in the development of various drug development processes.

CROs & CDMOs

The CROs & CDMOs segment is expected to show the fastest growth rate during the upcoming years, due to a surge in outsourcing of GMP-grade iPSC production. They also offer high technical expertise and affordable services, which lead to new collaborations, enhancing the development of iPSC cell therapies.

Regional Insights

Robust R&D Ecosystems Drive North America

North America dominated the iPSC cell therapies market in 2025, due to the presence of robust R&D ecosystems. The growth in healthcare investments and funding also increased the development of iPSC cell therapies. Additionally, early adoption of advanced technologies, stringent regulations, and growth in clinical trials also contributed to the market growth.

U.S. Market Trends

The growth in healthcare investments and the presence of robust research institutes and universities in the U.S. are increasing the advancements in iPSC cell therapies. The growing regulatory approvals are also increasing their adoption, where the growing technological advancements are also accelerating their development and innovations.

Expanding Biotech Hubs Boost Asia Pacific

Asia Pacific is expected to host the fastest-growing iPSC cell therapies market during the forecast period, due to expanding biotech hubs. The growing government support and chronic diseases are also increasing the demand for iPSC cell therapies. Moreover, growing R&D activities, collaborations, and expanding healthcare are also enhancing the market growth.

China Market Trends

China is experiencing a rapid growth in biotech startups and manufacturing capabilities, which are actively contributing to the development of new iPSC cell therapies. The growing government initiatives and increasing patient population are also increasing their innovation and adoption rates, respectively.

Europe Driven by Increasing Clinical Trials

Europe is expected to grow significantly in the iPSC cell therapies market during the forecast period, due to growing clinical trials. The presence of advanced research infrastructures and regulatory bodies are also encouraging their use and driving their advancements. Furthermore, growing collaborations, R&D activities, and government grants are also promoting the market growth.

UK Market Trends

The presence of robust research infrastructure in the UK is increasing the iPSC-based R&D activities, driving the development of new iPSC cell therapies. The increasing approval and government funding are also increasing their advancements, where the growing partnerships are also increasing their use in the development of personalized solutions.

iPSC Cell Therapies Market Value Chain Analysis

R&D

• The R&D of the iPSC cell therapies focuses on the development of off-the-shelf, gene-edited allogeneic therapies.
• Key players: Fate Therapeutics, BlueRock Therapeutics, Century Therapeutics.

Clinical Trials and Regulatory Approvals

• The safety, functional tissue integration, genomic stability, tumorigenicity, and immunogenicity are evaluated in the clinical trials and regulatory approval of the iPSC cell therapies.
• Key players: Fate Therapeutics, BlueRock Therapeutics, Cynata Therapeutics.

Patient Support and Services

• Long-term safety monitoring, clinical trial navigation, and genetic counselling are provided in the patient support and services of the iPSC cell therapies.
• Key players: Fate Therapeutics, BlueRock Therapeutics, Aspen Neuroscience.

Who are the iPSC Cell Therapies Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The iPSC cell therapies can be differentiated into any cell type, which is increasing their use in the development of various therapies.
• They provide a wide range of therapeutic applications, which is increasing their adoption rates.
• Their target-specific action is increasing their use in the development of personalized options, driving their acceptance rates.
• Moreover, their growing application in disease modelling and drug testing are also increasing their use.

Weaknesses

• The high cost associated with the personalized autologous therapies acts as the major weakness in the iPSC therapies market.
• The risk of immune rejection also reduces their acceptance rate.

Opportunities

• The growing chronic diseases like cardiovascular disease, diabetes, neurodegenerative diseases, etc., are increasing the demand for iPSC cell therapies.
• The growing adoption of regenerative medicines are also increasing the use of iPSC cells for their development.
• The growing innovation in gene-edited iPSC therapies is also driving their demand.
• The growing number of drug discoveries and clinical trials are also increasing their demand for toxicity testing.

Threats

• The iPSC cell therapies often undergo batch-to-batch variation, reducing the product consistency, limiting their use.
• Additionally, risk of contamination and complex manufacturing also reduce the sensitivity and quality of the iPSC cell therapies.

What are the Recent Developments in the iPSC Cell Therapies Market?

• In May 2025, the off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy developed for the treatment of spinal cord injury (SCI) by XellSmart Biopharmaceutical was announced to have received U.S. FDA and National Medical Products Administration (NMPA) of China approval for its Phase I clinical trial.
• In March 2025, the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) foundry, utilizing an integrated, on-site facility to develop clinical-grade iPSCs and derivative therapies with the use of the Nebula platform, will be launched by the collaboration between Cellino and Mass General Brigham’s Gene and Cell Therapy Institute (GCTI).

Segments Covered in the Report

By Therapy Type

• Allogeneic iPSC Therapies
• Autologous iPSC Therapies

By Derived Cell Type

• Cardiomyocytes
• Neurons/Neural Progenitors
• Hematopoietic & NK Cells

By Application

• Drug Discovery & Toxicology
• Regenerative Medicine

By End-User

• Pharmaceutical & Biotech Companies
• CROs & CDMOs

By Region 

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA